What's new? Log in Free sign up

Traws Pharma (TRAW)

Company Profile

Company profile

Ticker

TRAW

Exchange

Website

www.onconova.com/

CEO

Dr. Werner Cautreels Ph.D.

Incorporated

Location

Fiscal year end

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Mississippi Power • Alabama Power • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

ONCONOVA THERAPEUTICS INC, Onconova Therapeutics, Inc.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Onconova Europe GmbH ...

TRAW stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Definitive proxy

6 Feb 25

Prospectus supplement

Preliminary proxy

27 Jan 25

Notice of effectiveness

Shelf registration

15 Jan 25

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading

Prospectus supplement with pricing info

Departure of Directors or Certain Officers

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Change in insider ownership

WERNER CAUTREELS

Change in insider ownership

Nikolay Savchuk

ORBIMED ADVISORS LLC

ORBIMED ADVISORS LLC

Initial statement of insider ownership

Financial summary

Financial statements Chart TRAW financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	5.41 mm	5.41 mm	5.41 mm	5.41 mm	5.41 mm	5.41 mm
Cash burn (monthly)	3.83 mm	1.65 mm	2.85 mm	11.80 mm	3.83 mm	2.52 mm
Cash used (since last report)	16.34 mm	7.06 mm	12.15 mm	50.38 mm	16.34 mm	10.74 mm
Cash remaining	-10.93 mm	-1.65 mm	-6.74 mm	-44.97 mm	-10.93 mm	-5.33 mm
Runway (months of cash)	-2.9	-1.0	-2.4	-3.8	-2.9	-2.1

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

TRAW institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	8	31	-74.2%
Opened positions	1	10	-90.0%
Closed positions	24	4	+500.0%
Increased positions	0	7	EXIT
Reduced positions	5	6	-16.7%

13F shares	Current	Prev Q	Change
Total value	232.11 mm	1.29 bn	-81.9%
Total shares	15.93 mm	18.17 mm	-12.3%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Lincoln Park Capital Fund	13.64 mm	$8.65 mm	0.0%
Viriom	1.65 mm	$0.00	0.0%
Orbimed Advisors	605.53 k	$2.87 mm	-42.1%
Vanguard	26.72 k	$157.13 mm	-96.2%
BlackRock	9.96 k	$58.54 mm	NEW
UBS UBS	630.00	$3.70 mm	-99.4%
Vermillion & White Wealth Management	205.00	$1.21 mm	-96.0%
Pacific Capital Wealth Advisors	2.00	$12.00 k	-97.0%
Proequities	0.00	$0.00

Largest transactions	Shares	Bought/sold	Change
Vanguard	26.72 k	-680.20 k	-96.2%
Orbimed Advisors	605.53 k	-439.73 k	-42.1%
BLK BlackRock	0.00	-248.88 k	EXIT
Geode Capital Management	0.00	-224.09 k	EXIT
Renaissance Technologies	0.00	-218.09 k	EXIT
Citadel Advisors	0.00	-121.01 k	EXIT
UBS UBS	630.00	-97.95 k	-99.4%
STT State Street	0.00	-60.09 k	EXIT
NTRS Northern Trust	0.00	-30.66 k	EXIT
Virtu Financial	0.00	-27.36 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

TRAW insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
29 Dec 24	Nikolay Savchuk	Series A Warrant Common Stock	Buy	Acquire P	Yes	No	13.42	96,348	1.29 mm	96,348
29 Dec 24	Nikolay Savchuk	Pre-Funded Warrant Common Stock	Buy	Acquire P	Yes	No	0.01	96,348	963.48	96,348
29 Dec 24	Tpav	Series A Warrant Common Stock	Buy	Acquire P	No	No	13.42	96,348	1.29 mm	96,348
29 Dec 24	Tpav	Pre-Funded Warrant Common Stock	Buy	Acquire P	No	No	0.01	96,348	963.48	96,348
29 Dec 24	Werner Cautreels	Series A Warrant Common Stock	Buy	Acquire P	No	No	13.42	96,348	1.29 mm	96,348
29 Dec 24	Werner Cautreels	Pre-Funded Warrant Common Stock	Buy	Acquire P	No	No	0.01	96,348	963.48	96,348
29 Dec 24	Orbimed Advisors	Series A Warrant Common Stock	Buy	Acquire P	Yes	No	13.42	96,348	1.29 mm	96,348
29 Dec 24	Orbimed Advisors	Pre-Funded Warrant Common Stock	Buy	Acquire P	Yes	No	0.01	96,348	963.48	96,348

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

12 Health Care Stocks Moving In Thursday's Pre-Market Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket

Expert Systems Announced Milestone in Traws Pharma's H5N1 Program; Tivoxavir Marboxil Shows Broad-Spectrum Efficacy In Phase 1 Trial With No Adverse Events; Single Dose Maintains Plasma Levels Above EC90 For Over 23 Days

12 Health Care Stocks Moving In Monday's Pre-Market Session

Press releases

From Benzinga Pro

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Phase I completed in healthy volunteers with pharmacokinetic data supporting dosing for both therapeutic and further development for bird flu prevention NEWTOWN, Pa., Jan. 23, 2025 /PRNewswire/ -- Traws Pharma, Inc.

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

SAN DIEGO, Jan. 10, 2025 /PRNewswire/ -- Expert Systems, a hybrid AI enabled drug discovery and development accelerator, announced a significant milestone in a development of Traws Pharma, Inc. 's (NASDAQ:TRAW) H5N1

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval

Initial tranche of $20 Million extends cash runway into 1H26, subsequent tranche of up to $52.6 Million will provide for runway 3+ years enabling the company to reach both near-term and long-term value inflecting

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.